Breakthrough Pathway Final Guidance Eases Sponsor-Regulator Interaction Requirements
Executive Summary
US FDA issued a final guidance that sets out requirements for its new Breakthrough Devices Program mandated by Congress. Under the new program, which replaces the Expedited Access Pathway, sponsors have more certainty about how quickly they will get responses from the agency and fewer requirements when setting up early interactions.
You may also be interested in...
Start-Up Spotlight: Cognoa Seeks Breakthrough In Early Diagnosis Of Autism And ADD
US FDA recently granted Cognoa’s autism diagnostic device a Breakthrough Device designation to accelerate its efforts to get the first FDA-cleared medical device for the early diagnosis of autistic spectrum disorder (ASD) to market. The average age of ASD diagnosis is about four years old, but extensive clinical research has shown that earlier diagnosis of ASD can improve outcomes over the child’s lifetime. Cognoa’s system is intended to allow primary care physicians to diagnosis ASD in the children as young as 18 months.
US FDA Panel Meeting Set For Alzheimer’s Device Treatment
An Alzheimer’s treatment device from Israeli firm Neuronix Ltd has landed a date with US FDA’s Neurological Devices Panel. The committee will discuss the neuroAD Therapy System on March 21.
Sequana Medical Launches Belgian IPO
Sequana Medical has launched an IPO on Euronext Brussels a few days after the US FDA granted a breakthrough device designation to Sequana’s alfapump for liver ascites.